Compositions, organisms and methodologies employing a novel human kinase

• US 20080153147A1
• Filed: 11/05/2007
• Published: 06/26/2008
• Est. Priority Date: 11/27/2002
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Chen, Huimin, Liu, Wei, Wu, Leeying
• Application Number:
  US11/982,836
• Publication Number:
  US 20080153147A1
• Time in Patent Office: Days
• US Class Current: 435/194
• CPC Class Codes: C12N 9/1205 Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Abstract

This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK1. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 11q13 of human chromosome 11. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

Claims

1. An isolated polynucleotide comprising a nucleic acid sequence which encodes the amino acid sequence depicted in SEQ ID NO:

2.

2. The polynucleotide according to claim 1, wherein the nucleic acid sequence is selected from the group consisting of

(a) the nucleic acid sequence as shown in SEQ ID NO:

1;

(b) the complement of (a); and

(c) a nucleic acid sequence that differs from (a) or (b) due to the degeneracy of genetic code.

3. The polynucleotide according to claim 1, wherein the nucleic acid sequence is selected from the group consisting of:

(a) the nucleic acid sequence as shown in SEQ ID NO;

3;

(b) the complement of (a); and

(c) a nucleic acid sequence that differs from (a) or (b) due to the degeneracy of genetic code.

4. (canceled)

5. An isolated polynucleotide comprising a nucleic acid sequence which has at least 96% sequence identity with the sequence depicted in SEQ ID NO:

1, or the complement thereof.

6. The polynucleotide according to claim 5, wherein said nucleic acid sequence encodes a protein having MRCK activity.

7. (canceled)

8. An isolated polypeptide comprising a fragment of SEQ ID NO:

2, wherein said fragment comprises at least 260 consecutive amino acid residues.

9. The isolated polypeptide according to claim 8, wherein said fragment comprises amino acid residues 70-337 of SEQ ID NO:

2.

10-23. -23. (canceled)